




DOCKET NO.: 0018-1043-0 DIV

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

STEPHEN G. BAXTER
(703) 413-3000
SBAXTER@OBLON.COM

RE: Patent No.: 6,265,536

Patentee: Hidenori OHKI et al

Issued: July 24, 2001

For: CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC
ACTIVITY

SIR:

Attached hereto for filing are the following papers:

TERMINAL DISCLAIMER (EXECUTED BY ATTORNEY OF RECORD)

Our credit card payment form in the amount of \$130.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. §1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Certificate

APR 12 2007

of Correction

Stephen G. Baxter


Registration No. 32,884

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

DOCKET NO.: 0018-1043-0 DIV



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT OF: Hidenori OHKI et al

PATENT NO.: 6,265,536

ISSUED: July 24, 2001

FOR: CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY

TERMINAL DISCLAIMER

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Now comes the undersigned, Attorney of Record in the above-identified patent, who avers as follows:

Astellas Pharma Inc. is the owner of the entire right, title and interest in and to the invention claimed and disclosed in the above-captioned patent by virtue of Assignment, said Assignment having been recorded in the U.S. Patent and Trademark Office May 9, 2005 at Reel No. 016195, Frame No. 0824.

Astellas Pharma Inc. hereby disclaims the terminal part of the above-captioned granted patent, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 and §173 as presently shortened by any Terminal Disclaimer of U.S. Patent No. 6,107,458, and hereby agrees that the above-captioned granted patent shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,107,458, this agreement to run with the above-captioned granted patent and to be binding upon the grantee, its successors or assigns.

Astellas Pharma Inc. does not disclaim any terminal part of above-captioned granted patent that would extend to the full statutory term as defined in 35 U.S.C. §154 and §173 as presently shortened by any Terminal Disclaimer of U.S. Patent No. 6,107,458 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any Terminal Disclaimer, except for the separation of legal title stated above.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Apr: 19, 2007
Date Signed

Stephen G. Baxter
Stephen G. Baxter
Registration No. 32,884

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

04/10/2007 SZEWDIE1 00000001 6265536

01 FC:1814

130.00 0P